Coller IP advises many investors, companies and other entities who need to value, protect and monetize their Intellectual Property and wider Intangible Assets.
The following is a list of some venture capital companies who focus either exclusively or in part on the healthcare/biotech/biomedical area.
3i invest in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on those with high growth potential and strong management. In healthcare they invest in three core sub-sectors – pharmaceuticals and biotechnology, healthcare services and medical devices and technology.
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. They invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.
Founded in 1981, Advent Venture Partners have a focus on venture and growth investment in two sectors: Life Sciences and Technology. They aim to invest in early and mid-stage life science companies including in the areas of new drug discovery, enabling technologies, med tech and diagnostics.
Albion Ventures LLP claims to be one of the largest independent VC investors in the UK, managing approximately £230 million. Albion Ventures was created in January 2009 and looks to invest £1-10 million in a wide range of growing businesses.
Alta Partners is a venture capital firm specialising in life sciences, funding over 145 companies in the industry since 1996, including in the biopharmaceuticals, medical technology and IT sectors. They look for companies developing products or technologies which provide a barrier to competition through technological dominance or strong intellectual property.
Amadeus Capital Partners Limited is a venture capital company specialising in high-technology investments in the UK and Europe. Offices in London, Cambridge (UK) and San Francisco.
Apax Partners is an independent partnership. Funds advised by Apax Partners (‘Apax Funds’) typically invest in companies with a value of between €1bn and €5bn. The Funds invest in five sectors including healthcare.
Apposite Capital is an independent investment firm focussed exclusively on Healthcare. Apposite makes private equity investments in Healthcare Services companies, provides venture capital to Life Sciences companies, and makes investments in the direct secondary market.
ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in sectors including life sciences, such as biotech/pharmaceuticals, informatics ad medical devices.
Atlas Venture invests primarily in early stage technology and life sciences businesses in the U.S. and Europe, and are based in Cambridge, MA. Atlas that the bulk of their investments occur at the earliest stages and regularly play an active role in company formation.
Bay City Capital LLC
Bay City Capital was established in 1997 and manages investment funds in the life sciences industry, including the various sectors and with companies at all stages of development.
BVP has offices in New York, Silicon Valley, Boston, Mumbai and Herzliya and claim to manage more than $4billion of venture capital invested in over 130 companies. BVP have invested in healthcare related companies for more than 20 years and are currently looking for investment opportunities in healthcare services, healthcare IT, therapeutics and diagnostics.
Burrill & Company is a diversified global financial services company including venture capital / private equity. They have an exclusive focus on life sciences and invest in all sectors of biotechnology including human healthcare, devices, medical technology, nutraceuticals, agbio and enabling technologies. The average investment made by Burrill is $5-15million over the life of any one company.
Founded in 1987, Canaan Partners are a venture capital firm focussed on technology and healthcare, in particular biopharmaceuticals, medical devices and diagnostics. They typically invest $1 million to $20million at any stage of development, from seed financings to late stage investments.
Clarus Ventures is a dedicated life sciences venture capital firm which invests in both biopharmaceutical and medical device arenas. Clarus claim to currently manage $1.2 billion of assets across two funds.
Delta Partners is a venture capital firm investing primarily in Ireland and the United Kingdom. The firm has a focus on investing in early stage companies in two sectors: Technology-based Businesses and Medtech and Other Healthcare.
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With more than $2.57billion of capital raised, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s interests include therapeutics and medical devices, clinical diagnostics and healthcare IT.
ECI is one of the longest established private equity groups in the UK, specialising in buyouts, buy-ins and development capital deals valued between £10 and £150 million. ECI consider investing across the full range of the healthcare spectrum, including healthcare services, pharmaceuticals, medical technologies and healthcare IT. Offices based in Manchester and London.
The Entreprenuers Fund provides early stage and growth financing and areas of technology of interest include life-sciences, clean tech, materials and (online) retail related technology.
Esperante is a Netherlands-based life sciences investments company incorporated in 2004 and invests in companies developing novel human therapeutics in clinical or near-clinical development phase and in diagnostics and biomarkers. A typical investment is EUR200,000 to EUR 1 million per project per year and Esperante seeks a return on its investment within 3 to 5 years.
Established in 1985, Essex Woodlands claim to have $2.5 billion under management. Their focus is on investments across the healthcare sector including pharmaceutical, biotechnology, medical devices, healthcare services and healthcare IT. Essex Woodland’s investments include seed, late venture, growth equity, PIPE and buyout financings with a majority of capital geared towards the last three.
ETCapital invests in high-growth companies based in Southern England exploiting the innovative application of technology. Offices are based in Cambridge.
Excalibur Fund Managers is a specialised venture investor in life sciences companies managing and advising three funds, worth in excess of €450 million of equity capital. Excalibur invests in companies that are bringing to market human medicines or medical devices with ground breaking technology and significant commercial potential.
A division of Fidelity Investments which invests in private biopharmaceutical, medical technology, and healthcare IT and services companies.
Flagship Ventures is an early stage venture capital firm focused on life science solutions. Founded in 2000, Flagship manages over $900 million in early-stage funds with an active portfolio of over 40 companies. Initial investments may range from $500,000 and $5million, and typical investment is up to $7-$15 million during the life of a venture.
Forbion Capital Partners are specialised in the evaluation of late stage preclinical / early stage clinical development programs and medical device companies that are close to market approval. Current funds under management exceed EUR 450 million, split between four active funds and comprising some 27 promising portfolio companies.
Fountain Healthcare partners is an Irish based life science VC fund which was spun out from Elan Corporation’s New York based corporate venture capital group. Specific areas of interest are speciality pharma, medical devices, biotechnology and diagnositics., and they aim to deploy the majority of our capital in Europe with a strong focus on Ireland.
Frazier Healthcare invests exclusively in healthcare and provides growth equity and venture capital to high growth and emerging health care companies. In recent times, venture allocation has been focussed on companies that are developing biopharma therapeutics that have potential for near-term revenue in large markets and/or pre-revenue exits.
HBM are based in Switzerland and look to invest in human medicine, biotechnology, medical technology and diagnostics. The company holds and manages an international portfolio of around 25 companies and the focus of investment is on follow-on financing for existing portfolio members
HealthCare Ventures is a leading venture capital firm specializing in life science industry investing in pre-clinical or early clinical stage. Their approach is to identify high potential products within academia or pharmaceutical companies, develop them to clinical proof of concept within capital efficient, semi-virtual organisations.
HTGC work with life sciences companies at all stages of development from developing novel drug therapies to production of cost-saving medical devices. Life Science companies can leverage Hercules debt financing solutions to speed time to market, broaden scope of their clinical development and research, invest in new capabilities or shore-up the balance sheet ahead of IPO or negotiations with strategic partners.
Index ventures invest in companies in the fields of IT and the life sciences. In 2012, Index Ventures launched its first fund solely dedicated to the life sciences with GlaxoSmithKline and Johnson & Johnson to invest in early-stage biotechnology companies.
InterWest Partners is a venture capital firm based in California that invests in early-stage IT and healthcare. The healthcare team invests capital in a preclinical and clinical stage firms as well as companies with commercial assets. An average of $10 to $15 million is invested over the span of our involvement with a company.
InterPharm Investments Ltd are building a product portfolio by co-financing the devilment of innovative healthcare products, with a focus is on the OTX sector including medical foods and medical devices.
Inventages is focussed on life-sciences, nutrition and wellness with $1.5 billion under management. They invest in all stages of company development with a normal investment size of between $5million and $25million
Life sciences has been an investment focus area for KPCB since the firm’s inception in 1972, including the medical, healthcare and biotech fields. They claim to have built more than 100 life science companies including therapeutics and medical devices, drugs, vaccines, personalised medicine, diagnostics, healthcare IT and services. KPCB invests across all stages of new ventures including seed, early and growth funds.
Kurma Life Science Partners aim to be a key player in venture capital, development capital and technology transfer operating in the field of life sciences including biotechnology, health, medical sciences, nutrition and environmental sciences. It operates through an investment fund and strategic partnerships with medical research centres in France and the rest of Europe.
London Seed Capital Limited (LSC) is a seed and early-stage venture capital fund. London Seed Capital was established as a co-investment fund, which means that LSC only invests where its investment is at least matched by business angels. It can invest a maximum of £100,000 in the first round, alongside a minimum of £100,000 of business angel investment.
LSC operates in conjunction with the London Business Angel network (LBA) .
Longbow specialises in the early stage, development and expansion phases of the growth of unquoted life sciences companies. Typically, Longbow claim to invest in tranches of between £250,000 and £2.5 million and where an exit is achievable within 3 to 5 years.
Longwall Venture Partners is an Oxford based venture capital fund management company specialising in early stage investments in science, technology and engineering start-ups.
Lundbeckford Ventures is an evergreen life science venture fund wholly owned by the Lundbeckford Foundation. Lundbeckford Ventures invests up to EUR50 million on an annual basis and their focus is mainly later stage drug development, medtech and diagnostics. They aim to primarily invest in clinical projects and are particularly interested in the speciality pharma sector.
Mtf is an investment fund focused exclusively on the University of Manchester. It provides early-stage equity funding to help create new university spin-out companies.
Mercia provides investments to businesses seeking early stage support and provides expansion and development capital to predominantly unquoted cash generative UK based companies. MFM has a contractual relationship with a number of universities, including Birmingham and Warwick.
MPM Capital claims to be one of the world’s largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital invests globally in healthcare innovation. They invest in biotechnology, speciality pharma and medical technology at all stages of development and all therapeutic areas.
MTI is headquartered in the UK, and with a US office in Boston, its portfolio of investments includes companies in the Cleantech & Materials Technology and Medical Technology sectors. MTI focusses on early stage companies, in particular those associated with, or spun-out from, universities.
MVM maintains offices in London and Boston and has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare IT, healthcare services, medical devices, OTC medicines, research tools and vaccines. Their focus is on venture capital and growth equity investments in both early stage and late stage companies.
NeoMed Management is an investment firm, exclusively focussed on the healthcare industry with offices in Norway and Switzerland. NeoMed has a multi-stage investment approach and invests in all stages of development from start-up to later stage growth financings primarily in pharmaceutical, medical device and diagnostics.
NEA has offices in the US, China and India and invests in companies in three key domains- IT, healthcare and energy technology. Within the healthcare sector NEA has a focus in biopharmaceuticals, healthcare services and medical devices and offers support at any stage, from seeding innovations in emerging markets to funding early-stage companies in high growth markets to growth of market leaders.
New Hill Management invests in unlisted growth companies primarily in the UK. They are active in the private equity secondary market and also make primary investments in promising companies.
NLV Partners have offices in New York and San Mateo, CA and are a healthcare technology investor, managing approximately $1 billion in funds, and investments in 49 companies. NLV have a focus on three sectors: biopharmaceuticals, medical devices and information convergence. Investments are made at all stages.
Internationally oriented investment fund providing direct investments to small-medium sized companies with the aim of bridging the gap between funding new ventures at the early stage of conception and more main stream venture capital at a later stage of company development.
OrbiMed claim to be the world’s largest healthcare-dedicated investment firm, with approximately $7 billion in assets under management. They invest from seed-stage venture capital to large publicly-traded corporations.
Oxford Bioscience Partners are an early stage venture capital firm that provide equity financing and management assistance to innovative companies within the life sciences, energy and healthcare sectors. Their investment focus is on the U.S. and Korea and primarily in pre-commercial stage companies.
Oxford Capital Partners is a specialist investment manager with a portfolio that spans three super-growth themes: sustainability, healthcare and communications. In the healthcare sector their focus is on healthcare technologies such as medical devices, diagnostics, drug delivery, speciality pharma, life science research tools and other enabling technologies.
Pappas Ventures is soley focussed on investing in the life sciences – biotechnology, speciality pharma, drug delivery and medical devices. They claim to have $350 million under management and invest the largest share of their capital in companies whose lead products are at the Phase 1 and Phase 2 stage of development and who are based in North America.
Phase4 Ventures was spun-out of Nomura in 2010 and are based in London. They invest in development stage life science companies in the US and Europe and typically invest between $10 and $25 million initially with the potential of up to $40million over the life of an investment.
Polaris Venture Partners is a partnership of venture capital investors and technology executives. Its mission is to identify and invest in seed, first round, and early stage information technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies.
ProQuest Investments is a healthcare VC firm which claims to have ~$900 million under management. They invest in companies from seed to late-stage and average investments range from $250,000 to $25 million and have a particular focus in therapeutics.
Prospect Venture Partners in a California based venture capital firm which is focussed on biopharmaceutical and medical device companies. They aim to ultimately invest $10-$20 million in each company as a lead investor or as a co-lead in an investor syndicate.
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. They aim to invest at all stages of development and typically invests between $5million and $25million in each company.
Rock Spring Ventures invest in early-stage, high-growth life science and health technology companies in the US and UK. RSV’s focus is on providing equity capital to young companies including university spin-outs that are currently developing commercial applications of novel research.
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling emphasis is on early-stage financing and active management of its portfolio companies.
SEP claim to have invested in over 150 companies since 1991 and have a have a sector focus on software, media, e-commerce, healthcare and energy. They typically invest from £5 million to £15 million of growth equity either as sole or lead investor.
Seroba Kernel is based in the UK and Ireland and are an established life sciences VC firm. They invest in companies in all stages of their operation in therapeutics and medical devices. In therapeutics they invest at early stages of clinical development but are also willing to invest at preclinical stages.
Seventure Partners were established in 1997 and claim to have almost EUR600 million under management. They finance in two sectors: Information and Communication Technology (ICT) and Life Sciences. In Life Sciences, Seventure support the development of companies from seed rounds of financing to development capital for companies carrying up to EUR50 million turnover.
Sofinnova Ventures has over 30 years of experience building start-ups and spin-outs into market leaders. With $1 billion under management, the firm applies capital and expertise to guide early stage companies to successful exits.
Skyline Ventures invest in product-focused healthcare companies and have expertise in small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research. They target investments of $15-$35 million per portfolio company over the life of the company.
Spark Ventures is an early stage European Venture Capital company with a focus on high growth technology, media and healthcare companies in the UK and Europe.
Sunstone Capital is headquartered in Copenhagen and is an early stage Life Science and technology venture capital company investing in European start-up companies. They invest in opportunities across the life sciences sector including therapeutics, medical technology and diagnostics. And typically make an initial investment in companies raising Series A/B rounds.
SV Life Sciences is an international life sciences investment firm and claims to manage approximately $2.0 billion of capital . They have offices in Boston , London and San Francisco and invest in biotechnology, medical devices and healthcare services and technology .
Syncona Partners LLP was founded in 2012 and operates as an evergreen investment company. They are an independent subsidiary of the Wellcome Trust and will support healthcare products (devices, therapeutics, diagnositcs, IT), services and business models. They invest on a global basis and will support early stage and late stage companies.
Third Rock Ventures was founded in 2007 and is a life-sciences investment firm with offices in Boston and San Francisco. Their investments are often at an early stage and collaborations with big pharma and biotech are encouraged. They claim to have raised more than £1.3 billion and invested in more than 31 companies since 2007.
TPG Biotech is the life science venture arm of TPG, a global private investment firm. They invest across life science sectors, geographies, company stages and asset classes
TVM Capital Life Sciences operate from offices in Montreal, Munich and Boston Since 9184, TVM Capital have made almost 120 investments in life science companies in Europe and the US and claim to currently manage in excess of EUR 900 million. In pharmaceuticals their approach is based on the development of single pharmaceutical assets to human proof-of-concept with high capital efficiency.
Venrock is a premier venture capital firm with offices in Palo Alto, New York, Cambridge, MA. Originally established as the venture capital arm of the Rockefeller family, Venrock have a current focus on healthcare and technology.
Versant Ventures is a venture capital firm that specialises in investments in medical devices, biopharmaceuticals and other life science opportunities. They invest throughout the US, Western Europe and Canada and investments range from an initial investment of $250,000 up to a total investment of $30 million.
Warburg Pincus is a private equity investor which was established more than 40 years ago. They claim to have invested more than $45 billion in over 675 companies. In healthcare they primarily invest in medical devices, healthcare services and pharmaceuticals.
Ysios Capital is an independent Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies.